|Videos|June 17, 2014

What's New in Metastatic Breast Cancer Research

Nancy Lin, MD, of the Susan F. Smith Center for Women's Cancers at the Dana Farber Cancer Institute, discusses the differences between breast cancer subtypes and looks at recent drug approvals and research directions for the future.

Nancy Lin, MD, of the Susan F. Smith Center for Women’s Cancers at the Dana Farber Cancer Institute, discusses the differences between breast cancer subtypes and looks at recent drug approvals and research directions for the future.

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

What's New in Metastatic Breast Cancer Research

Related Content

Bringing Bispecific Therapy Into the Outpatient Community Oncology Setting

How AON Supports Safe Outpatient Bispecific Therapy in Community Oncology

Bispecific Therapies Expand Outpatient Treatment Options for Lymphoma and Leukemia

PPI, Antibiotic Exposure Associated With Attenuated Immunotherapy Benefit in Stage 3 NSCLC

The Weekly Dose: Cyclosporiasis Outbreak Grows, AI-Powered Refills Pilot, and New FDA Approvals in Alzheimer Disease

Latest CME

Innovations in Hidradenitis Suppurativa Treatment: Navigating the Evolving Landscape

NEIAP Conference 2026

NEIAP 2026 Annual Forum

Navigating the Legal Landscape of Telehealth: Updates and Implications for Pharmacists and Technicians (Pharmacy Technician Credit)

Reducing the Treatment Burden in HIV Management: The Pharmacist’s Role in Long-Acting Injectable Adoption

Optimizing Lipid Management in Statin-Intolerant Populations: Payer Strategies for Evidence-Based Access and Risk Reduction

Effective Strategies to Manage Hyperglycemia When Treating with PI3K and AKT Inhibitors

Beyond the Nasal Passage: Managing Chronic Rhinosinusitis With Nasal Polyps With Biologics and Pharmacist-Led Approaches

HER2-Positive Metastatic Breast Cancer: A Managed Care Perspective on Emerging Therapies and Clinical Data

Sugar, We’re Going Down: Navigating Glycemic Control in the Era of PI3K/AKT Inhibition for Breast Cancer

Collaborative Practice Agreement Implementation and Adherence: A Practical Roadmap for Oncology Pharmacists

From Payload to Patient: Managing Toxicities of Antibody-Drug Conjugates Directed at HER2 and TROP2

Exploring Immunotherapy Strategies in Endometrial Cancer

Best Practice Approaches for Understanding Chronic Obstructive Pulmonary Disease and Precision Medicine Treatment

Hat Trick for Hypertension: Strategies to Improve Outcomes With Single-Pill Combinations

Updated Guidance and Managed Care Strategies to Optimize Care in EGFR Mutated NSCLC

Lymphoma Day of Education 2026

Two Targets, One Mission: Optimizing Bispecific Antibody Use in Non-Hodgkin Lymphoma

Breaking Barriers in Asthma Care: Exploring the Role of Type 2 Inflammation and Biologic Therapies

Navigating the Legal Landscape of Telehealth: Updates and Implications for Pharmacists and Technicians

Lymphoma Day of Education 2026

Clinical Presentation of Hyperglycemia with PI3K and AKT Inhibitors

Cardiorenal Protection With SGLT2 Inhibitors: Perspectives for Managed Care

Transforming Gout Care: Navigating Barriers and Therapeutic Advances in Disease Management

Optimizing Bispecific Antibody Therapy in Relapsed/Refractory Lymphomas: A Practical Guide for Pharmacists

Outsmart the Algorithm: Combatting Misinformation at the Pharmacy Counter

Expanding the Role of Long-Acting Injectables in Optimizing Schizophrenia Management

VMAT2 Inhibitors for Long-Term Success in Tardive Dyskinesia

Shifting Perspectives in Treatment-Resistant Depression: Novel Therapies and Patient-Centered Care

Navigating Adverse Effects in HR+/HER2-Negative Metastatic Breast Cancer: Tailored Management Plans and Pharmacist Interventions for Improved Outcomes

Optimizing Therapy in HR+/HER2-Negative Metastatic Breast Cancer: Navigating Novel Treatments and Personalized Care

Bridging Knowledge Gaps in HR+/HER2– Early-Stage Breast Cancer

Optimizing HER2-Directed Therapy in Metastatic Breast Cancer: From HER2-Positive to HER2-Ultralow

Translating KDIGO Updates and Clinical Evidence Into Managed Care Decision-Making in IgA Nephropathy

From Flares to Freedom: Navigating the Journey of Patients With Chronic Spontaneous Urticaria With Next-Generation Therapies

Shaping the Future of Generalized Myasthenia Gravis Management: A Focus on Novel Treatment Approaches

Expert Insights on the Horizon of HER2-Directed Therapy

Type 2 Inflammation in Focus: Advancing Pediatric Atopic Dermatitis Care With Biologic Therapies

Chronic Obstructive Pulmonary Disease and Inflammation: Practical Approaches to Integrating Biologic Therapy

Understanding Type 2 Inflammation and Its Role Across Various Immune-Related Diseases

Innovations in Lymphoma Treatment and the Growing Impact of Bispecific Antibodies

Addressing the Burden of Hemolysis in Paroxysmal Nocturnal Hemoglobinuria: The Pharmacist's Contribution to Patient Care

Payment for Pharmacist Services: 2025 Update

From Treatment to Prevention: Navigating the Expanding Hereditary Angioedema Treatment Landscape

The Oncology Pharmacist's Role in Managing Small Molecule Inhibitor Use in Chronic Lymphocytic Leukemia to Enhance Patient-Centered Care

Redefining Complement-Mediated Kidney Disease: The Latest in Diagnosis and Treatment

The Educated Pharmacist - Weighing In: Translating Evidence to Practice — A Multidisciplinary Analysis of Obesity Pharmacotherapy Implementation and Team-Based Care

Advancing Pharmacist Expertise in R/R FL: Navigating Novel Therapies and Optimizing Patient Outcomes

Paroxysmal Nocturnal Hemoglobinuria: Managed Care Strategies to Mitigate Burden and Enhance Outcomes

Optimizing Outcomes in Myasthenia Gravis: Therapeutic Advances and Value-Based Care Models

Navigating Novel Therapies in Steroid-Refractory cGVHD: Practical Strategies for Community-Based Oncology Pharmacists

Reducing Transfusion Burden in Myeloid Disorders: Novel Therapeutic Strategies and Pharmacist Interventions

Panel Discussion: Integrating Novel Combinations and Earlier Line Use in Diffuse Large B-Cell Lymphoma

Optimizing Patient Outcomes in R/R DLBCL: Bridging Knowledge Gaps for Oncology Pharmacists in the Era of Novel Immunotherapies

Clinical Panel Debate: CAR T-Cell Therapy vs Bispecific Antibodies

From Molecules to Medicine: Pharmacologic Principles of Innovative Non-Hodgkin Lymphoma Therapies

The Pharmacist's Role in Palliative and End of Life Symptom Management (Pharmacy Technician Credit)

The Pharmacist's Role in Palliative and End of Life Symptom Management

Understanding mRNA Vaccines: Dispelling Myths and Empowering Pharmacists to Counsel Patients (Pharmacy Technician Credit)

Understanding mRNA Vaccines: Dispelling Myths and Empowering Pharmacists to Counsel Patients

Precision Matters: Foundations of Biomarker-Driven Care in Non-Small Cell Lung Cancer

From Testing to Treatment: Empowering Pharmacists to Overcome Barriers and Optimize Biomarker-Driven Care

Exploring Oncolytic Viruses in Melanoma: Pharmacist-Led Approaches for Safe Integration

Addressing Vaccine Hesitancy in Infectious Disease Prevention

Protecting Against Meningococcal Disease: Updates on Vaccines, Guidelines, and Pharmacist Best Practices

Targeting the Root of Autoimmunity in Generalized Myasthenia Gravis: Pharmacist Strategies for Integrating FcRn Therapies Into Specialty Practice

IL-23 Inhibitors in Psoriasis: Optimizing Access and Patient Outcomes Across Integrated Systems

Utilizing VMAT-2 Inhibitors for the Management of Tardive Dyskinesia: The Role of Long-Term Care Pharmacists

The Expanding Therapeutic Landscape in IgA Nephropathy: Translating New Clinical Evidence and Updated Guidelines Into Managed Care Strategies

The Expanding Therapeutic Landscape in IgA Nephropathy: A Case-Based Exploration of Optimized Patient Outcomes

Influenza Immunization in Older Adults: Enhanced Vaccines and Best Practices for Long-Term Care Pharmacists

From Guidelines to Action: Implementing Pneumococcal Vaccine ACIP Recommendations in Long-Term Care Settings